Found: 7
Select item for more details and to access through your institution.
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1591, doi. 10.1177/13524585221083194
- By:
- Publication type:
- Article
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 10, p. 1564, doi. 10.1177/1352458520971819
- By:
- Publication type:
- Article
(DXT10) Siponimod Affects Disability Progression in Patients with Secondary Progressive Multiple Sclerosis Independent of Relapse Activity: Results from the Phase 3 EXPAND Study.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 19
- By:
- Publication type:
- Article
Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrence.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
- Published in:
- Journal of Neurology, 2022, v. 269, n. 9, p. 5093, doi. 10.1007/s00415-022-11166-z
- By:
- Publication type:
- Article
A proof of concept phase II non-inferiority criterion.
- Published in:
- Statistics in Medicine, 2011, v. 30, n. 13, p. 1618, doi. 10.1002/sim.3997
- By:
- Publication type:
- Article
Assessment of Nevirapine Bioavailability From Targeted Sites in the Human Gastrointestinal Tract.
- Published in:
- Journal of Clinical Pharmacology, 2009, v. 49, n. 12, p. 1417, doi. 10.1177/0091270009344856
- By:
- Publication type:
- Article